Search

Author/Creator Charles, Edgar D

1. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Issue 10165 (22nd December 2018)

Authors:
Sanyal, Arun; Charles, Edgar D; Neuschwander-Tetri, Brent A; Loomba, Rohit; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric J; Halegoua-DeMarzio, Dina; Kundu, Sudeep; Noviello, Stephanie; Luo, Yi; Christian, Rose
Journal:
Lancet
Issue:
Volume 392:Issue 10165(2018)
Page Start:
2705
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). Issue 1 (30th December 2021)

Authors:
Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi; Minnich, Anne; Zhan, Xiaojiang; Tirucherai, Giridhar S; Elpers, Brandon; Xiao, Hong; Watanabe, Hideaki; Smith, R Adam; Charles, Edgar D; Fischer, Aryeh
Journal:
BMJ open respiratory research
Issue:
Volume 8:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search